ArticleJournal for immunotherapy of cancer2022

Correction: Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study.

No numbers read from the abstract.

Not cited yet